ArticleActa neuropathologica2024
Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies.
Abstract read
In one paragraph
Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Associations of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Dynamic [Molecular neurodegeneration · 2026Article
- Emerging directions in tauopathy research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Tau conformation, distribution and PET imaging correlations in progressive supranuclear palsy.Translational neurodegeneration · 2026Review
- Article
- Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.Brain sciences · 2026Article
- From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.Frontiers in aging neuroscience · 2026Review
- A Biomarker-Based Classification of Corticobasal Syndrome.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Tau protein: Physiological functions and multifaceted roles in neurodegenerative and psychiatric disorders.Genomic psychiatry : advancing science from genes to society · 2025Article
- Developing a novel reference region for [European journal of nuclear medicine and molecular imaging · 2025Article
- Exploring the origins of frequent tau-PET signal in vermal and adjacent regions.European journal of nuclear medicine and molecular imaging · 2025Article
- Co-occurrence of multiple pathologies in a case of frontotemporal dementia with TBK1 mutation: first in vivo detection of alpha-synuclein and tau co-pathology.Acta neuropathologica communications · 2025Article
- Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Distinct reduction in relative microglial glucose uptake compared to astrocytes and neurons upon isolation from the brain environment.Frontiers in cellular neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Luna Slemann *Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Johannes Gnörich *Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Selina Hummel *Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Laura M Bartos *Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Carolin KlausGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Agnes KlingDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Julia Kusche-PalengaDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Sebastian T KunteDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Lea H KunzeDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Amelie L EnglertDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Yunlei LiDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Letizia VoglerDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Sabrina KatzdoblerGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Carla PalleisGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Alexander BernhardtGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Alexander JäckGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Andreas ZwergalDepartment of Neurology, LMU Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Franziska HopfnerDepartment of Neurology, LMU Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Sebastian N Roemer-CassianoDepartment of Neurology, LMU Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Gloria BiecheleDepartment of Radiology, LMU Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Sophia StöckleinDepartment of Radiology, LMU Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Gerard BischofCognitive Neuroscience, Institute for Neuroscience and Medicine (INM-3), Research Centre Juelich, Juelich, Germany.
Thilo van EimerenCognitive Neuroscience, Institute for Neuroscience and Medicine (INM-3), Research Centre Juelich, Juelich, Germany.
Alexander DrzezgaDepartment of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
Osama SabriDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
Henryk BarthelDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
Gesine RespondekDepartment of Neurology, Medizinische Hochschule Hannover, Hannover, Germany.
Timo GrimmerCenter for Cognitive Disorders, Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Jochen HermsGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Lars PaegerGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Marie WillroiderDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Leonie BeyerDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Günter U Höglinger *German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Sigrun Roeber *Center of Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, Germany.
Nicolai Franzmeier *Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Matthias Brendel *Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany. matthias.brendel@med.uni-muenchen.de.ORCID 0000-0002-9247-2843
Funding
Deutsche Forschungsgemeinschaft EXC 2145 SyNergy - ID 390857198
Abstract
Tau PET has attracted increasing interest as an imaging biomarker for 4-repeat (4R)-tauopathy progressive supranuclear palsy (PSP). However, the translation of in vitro 4R-tau binding to in vivo tau PET signals is still unclear. Therefore, we performed a translational study using a broad spectrum of advanced methodologies to investigate the sources of [
Indexed as
AstrocytesNeuronsOligodendrogliaPositron-Emission TomographyTauopathiestau ProteinsAgedAnimalsBrainDisease Models, AnimalFemaleHumansMaleMiceMice, TransgenicMiddle Agedtau ProteinsAutopsyAutoradiographyNeuronPETPI-2620Tau
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.